In this study, we report the identification of an immunomodulatory drug vidofludimus [2-(3-Fluoro-3′-methoxybiphenyl-4-ylcarbamoyl)-cyclopent-1-enecarboxylic acid (4SC-101)] as a novel modulator for FXR with a therapeutic potential in the treatment of NAFLD. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.